In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Kaiting YangDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0001-9328-5655 Christina A NowickiDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0001-8110-9021 Wei LiuDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0003-0696-6407 Kangdi LiDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0003-3737-6573 Emile NaccashaDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA.ORCID 0009-0005-5445-9313 Yang-Xin FuDepartment of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, P.R. China.ORCID 0000-0001-8441-6617 Hua LiangDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0001-5512-8595 Ralph R WeichselbaumDepartment of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-5643-8939 Funding
VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI KUNLE ODUNSI · 1985 to 2026
$122.1MGenetically-engineered Bacteria Overcome Therapy ResistanceR01CA292860 · NCI · UNIVERSITY OF CHICAGO · PI Mark Mimee, RALPH R WEICHSELBAUM · 2024 to 2026
$2.9MImmunoengineering Postdoctoral Training Program - Resubmission - 1T32AI153020 · NIAID · UNIVERSITY OF CHICAGO · PI ALEGRE, MARIA-LUISA, SWARTZ, MELODY ANN · 2021 to 2025
$2.1MElucidating the Roles of RNA m6A readers Y1 and Y2 in radiation-induced immunity and immunotherapyR01CA262508 · NCI · UNIVERSITY OF CHICAGO · PI WEICHSELBAUM, RALPH R · 2021 to 2025
$2.0MNCI NIH HHS P30 CA014599NCI NIH HHS R01 CA262508NCI NIH HHS R01 CA292860NIAID NIH HHS T32 AI153020
6 · The paper itselfAbstract
Pancreatic ductal adenocarcinoma (PDAC) presents a substantial challenge due to its resistance to cancer treatments. This limited efficacy is, in part, attributed to the immunosuppressive tumor microenvironment (TME), which impairs effector T (T
Indexed as
BifidobacteriumCarcinoma, Pancreatic DuctalInterleukin-2Pancreatic NeoplasmsProbioticsAnimalsCell Line, TumorHumansImmunotherapyMiceT-Lymphocytes, RegulatoryTumor MicroenvironmentInterleukin-2
Identifiers
PMID42490449
PMCPMC13394381
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390